SummaryBroadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection in animal models. Characterized bNAb targets, although key to vaccine and therapeutic strategies, are currently limited. We defined a new site of vulnerability by solving structures of bNAb 8ANC195 complexed with monomeric gp120 by X-ray crystallography and trimeric Env by electron microscopy. The site includes portions of gp41 and N-linked glycans adjacent to the CD4-binding site on gp120, making 8ANC195 the first donor-derived anti-HIV-1 bNAb with an epitope spanning both Env subunits. Rather than penetrating the glycan shield by using a single variable-region CDR loop, 8ANC195 inserted its entire heavy-chain variable domain into a ga...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) are promisin...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
SummaryThe HIV-1 envelope (Env) spike contains limited epitopes for broadly neutralizing antibodies ...
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are p...
The HIV-1 envelope (Env) spike contains limited epitopes for broadly neutralizing antibodies (bNAbs)...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...
The HIV-1 envelope (Env) spike contains limited epitopes for broadly neutralizing antibodies (bNAbs)...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
The HIV-1 envelope (Env) glycoprotein binds to host cell receptors to mediate membrane fusion. The p...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
The HIV-1 envelope (Env) glycoprotein binds to host cell receptors to mediate membrane fusion. The p...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) are promisin...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
Broadly neutralizing antibodies (bNAbs) to HIV-1 envelope glycoprotein (Env) can prevent infection i...
SummaryThe HIV-1 envelope (Env) spike contains limited epitopes for broadly neutralizing antibodies ...
Broadly neutralizing antibodies (bNAbs) against HIV-1 envelope (Env) inform vaccine design and are p...
The HIV-1 envelope (Env) spike contains limited epitopes for broadly neutralizing antibodies (bNAbs)...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1-infected individuals inform HIV-1 vaccin...
The HIV-1 envelope (Env) spike contains limited epitopes for broadly neutralizing antibodies (bNAbs)...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
The HIV-1 envelope (Env) glycoprotein binds to host cell receptors to mediate membrane fusion. The p...
HIV-1 broadly neutralizing antibodies are desired for their therapeutic potential and as templates f...
The HIV-1 envelope (Env) glycoprotein binds to host cell receptors to mediate membrane fusion. The p...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bN...
Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) are promisin...